SupportLoginSign Up
Featured FeedJournalsCollectionsKeywordsSaved Papers
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Add like
Add dislike
Add to saved papers

Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection.

Emilie Goguet, Cara H Olsen, William A Meyer, Sara Ansari, John H Powers, Tonia L Conner, Si'Ana A Coggins, Wei Wang, Richard Wang, Luca Illinik, Margaret Sanchez Edwards, Belinda M Jackson-Thompson, Monique Hollis-Perry, Gregory Wang, Yolanda Alcorta, Mimi A Wong, David Saunders, Roshila Mohammed, Bolatito Balogun, Priscilla Kobi, Lakeesha Kosh, Kimberly Bishop-Lilly, Regina Z Cer, Catherine E Arnold, Logan J Voegtly, Maren Fitzpatrick, Andrea E Luquette, Francisco Malagon, Orlando Ortega, Edward Parmelee, Julian Davies, Alyssa R Lindrose, Hannah Haines-Hull, Matthew S Moser, Emily C Samuels, Marana S Rekedal, Elizabeth K Graydon, Allison M W Malloy, David R Tribble, Timothy H Burgess, Wesley Campbell, Sara Robinson, Christopher C Broder, Robert J O'Connell, Carol D Weiss, Simon Pollett, Eric D Laing, Edward Mitre
Frontiers in Immunology 2024
INTRODUCTION: We sought to determine pre-infection correlates of protection against SARS-CoV-2 post-vaccine inzfections (PVI) acquired during the first Omicron wave in the United States.

METHODS: Serum and saliva samples from 176 vaccinated adults were collected from October to December of 2021, immediately before the Omicron wave, and assessed for SARS-CoV-2 Spike-specific IgG and IgA binding antibodies (bAb). Sera were also assessed for bAb using commercial assays, and for neutralization activity against several SARS-CoV-2 variants. PVI duration and severity, as well as risk and precautionary behaviors, were assessed by questionnaires.

RESULTS: Serum anti-Spike IgG levels assessed by research assay, neutralization titers against Omicron subvariants, and low home risk scores correlated with protection against PVIs after multivariable regression analysis. Commercial assays did not perform as well as research assay, likely due to their lower dynamic range.

DISCUSSION: In the 32 participants that developed PVI, anti-Spike IgG bAbs correlated with lower disease severity and shorter duration of illness.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.
Show additional links to paperHide additional links to paper
PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Do Not Sell My Personal InformationManage Cookie Preferences

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app